Alpha Cognition (ACOG) 10% Owner Inc. Buys $118K of Stock

Opaleye Management bought 14,283 shares of Alpha Cognition Inc. (ACOG) on October 16, 2026, continuing a steady series of purchases in the biopharmaceutical firm. According to a Form 4 filing with the SEC, the 10% owner executed the transaction at an average price of $8.23 per share, totaling roughly $117,600.

ACOG Alpha Cognition Inc.

$8.50 ▲ +30.77% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Opaleye Management's Alpha Cognition Trade

The purchase lifted Opaleye Management's holdings by 0.44%, bringing its total stake to 3,259,894 shares. This move extends a pattern of buying from the firm, which also added shares on September 25, September 16, and August 3 of this year. The trade was not made under a pre-arranged Rule 10b5-1 trading plan.

Other Institutional Activity in Alpha Cognition

Other major funds hold positions in the company alongside Opaleye Management. Opaleye Management grew its holdings by 333,560 shares, ending with 2,895,467 shares worth about $24.6 million. Solas Capital Management, LLC held 1,924,617 shares valued at roughly $16.4 million. AWM Investment Company, Inc. held 1,672,168 shares worth about $14.2 million. Cable Car Capital, LP held 1,382,339 shares valued at roughly $11.7 million. Ikarian Capital, LLC reduced its holdings by 220,024 shares, ending with 836,259 shares worth about $7.1 million.

Alpha Cognition Inc. Stock Up 3.8%

Alpha Cognition shares recently traded around $8.50 as of October 19, 2026. The stock sits below its 50-day moving average of $8.98 and above its 200-day moving average of $7.03. It trades below its 52-week high of $10.14 and above its 52-week low of $4.50. Analysts maintain a mean price target of $18.00 on the stock.

Recent Earnings

Alpha Cognition reported trailing-twelve-month revenue of $15.3 million with a net margin of -137.7% and a return on equity of -49.5%. The company posted trailing earnings per share of -$1.32. Its next quarterly financial report is scheduled for November 12, 2026.

Insider Buying and Selling at Alpha Cognition Inc.

Insiders have been active in the stock over recent months. Opaleye Management acquired 31,763 shares on September 25, 2026, and 123,918 shares on September 16, 2026. Earlier, Robert James Wills bought 10,000 shares at $9.62 per share on August 21, 2026, for a total value of $96,200. Opaleye Management also bought 52,900 shares on August 3, 2026.

Analysts Set New Price Targets

Wall Street firms have maintained positive outlooks on the company. On July 10, 2026, Raymond James initiated coverage with an Outperform rating and a $20.00 price target. HC Wainwright & Co. maintained a Buy rating on August 17, 2026, raising its price target to $20.00 from $18.00. B. Riley Securities initiated coverage with a Buy rating and a $21.00 price target on August 20, 2026. The stock carries a consensus strong buy recommendation.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a biopharmaceutical company based in Grapevine, Texas, focused on developing treatments for neurodegenerative conditions in the United States and Canada. Its primary commercial program includes ZUNVEYL, an oral tablet formulation intended for the treatment of Alzheimer's disease. Insider transactions from major stakeholders often draw attention as the firm advances its clinical and commercial goals.

Bottom Line

Opaleye Management's continued accumulation of shares increases its footprint in Alpha Cognition ahead of the company's next earnings report on November 12, 2026. Investors will monitor upcoming SEC filings and clinical updates to gauge ongoing institutional sentiment.